July 25, 2011
Biogen Idec said today it received conditional regulatory approval in Europe to market its drug Fampyra, a treatment to improve walking in patients with multiple sclerosis, a disease in which the body attacks the brain and spinal cord.
The European Commission approved the company’s tablet based on studies showing it increased walking speed up to 25 percent in adults with multiple sclerosis. The approval is conditional and regulators are requiring the company to conduct a long-term, follow-up study of the drug’s benefits. The approval will have to be renewed annually until full approval is granted.
Known generically as fampridine, Fampyra was developed by Acorda Therapeutics Inc., which markets it in the U.S. under the brand name Ampyra.
source: boston.com
..
Biogen Idec said today it received conditional regulatory approval in Europe to market its drug Fampyra, a treatment to improve walking in patients with multiple sclerosis, a disease in which the body attacks the brain and spinal cord.
The European Commission approved the company’s tablet based on studies showing it increased walking speed up to 25 percent in adults with multiple sclerosis. The approval is conditional and regulators are requiring the company to conduct a long-term, follow-up study of the drug’s benefits. The approval will have to be renewed annually until full approval is granted.
Known generically as fampridine, Fampyra was developed by Acorda Therapeutics Inc., which markets it in the U.S. under the brand name Ampyra.
source: boston.com
..
===========================================================
Remain CURRENT with Multiple Sclerosis news and information,
when registered at our MS Views and News website
.
.Providing You with 'MS Views and News', is what we do
.
On the 4th Wednesday of each month
Listen-to StuMSRadio.com at 8pm eastern time.
Each month will feature various guests to be interviewed
Call-in to have (5) minutes of airtime.
Speak about your MS or ask questions
.
Your donation will Help us to educate
"MS Views and News" is a 501©(3) Not-for-Profit organization as recognized by the Internal Revenue Service
.. All contributions are tax deductible to the fullest extent allowed by law
.===========================================================
Disclaimer: 'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
0 comments:
Post a Comment